FEATURE ARTICLE
Ru/PNNP-Catalyzed Asymmetric Ficini Reactions in Ligand Design
523
1 H, PhCHHN), 4.62 (d, J = 15.7 Hz, 1 H, PhCHHN), 3.73 (d, J =
tert-Butyl (1R,2S,5S)-7-(N-Benzyl-4-methylphenylsulfonami-
2.6 Hz, 1 H, bridgehead), 2.43 (s, 3 H, ArCH3), 2.30–2.20 (m, 1 H,
do)-6-cyclohexyl-2-[(dinaphtho[2,1-d:1¢,2¢-f][1,3,2]dioxaphos-
phepin-4-yl)oxy]bicyclo[3.2.0]hept-6-ene-1-carboxylate (8b)
Et3N (23 mL, 163 mmol, 3 equiv) and 4-chlorodinaphtho[2,1-d:1¢,2¢-
f][1,3,2]dioxaphosphepine35 (35.8 mg, 80%, 82 mmol, 1.5 equiv) in
CH2Cl2 (0.6 mL) were added to a stirred soln of 6a (30.0 mg, 54
mmol, 1 equiv) in CH2Cl2 (0.8 mL). The solvent was evaporated af-
ter 84 h and the crude product was purified by flash column chro-
matography (silica gel, hexane–EtOAc, 10:1) to give a white solid;
yield: 12.6 mg (14.6 mmol, 27%).
Hallyl), 1.71–1.60 (m, 3 H), 1.54–1.45 (m, 1 H), 1.39 (s, 9 H,
OC(CH3)3], 1.34–0.98 (m, 5 H), 0.92–0.78 (m, 1 H).
tert-Butyl (1R,2S,5S)-7-(N-Benzyl-4-methylphenylsulfonami-
do)-6-cyclohexyl-2-hydroxy-2-methylbicyclo[3.2.0]hepta-3,6-
diene-1-carboxylate (7c)
A 3 M MeMgI in Et2O soln (33 mL, 98 mmol, 1.05 equiv) was added
to a stirred soln of 7b (51.1 mg, 93 mmol, 1 equiv) in THF (2 mL) at
0 °C. After 15 min, the cooling bath was removed and the mixture
was stirred for 1 h at r.t. The reaction was quenched by the addition
of H2O and brine. The soln was extracted with Et2O (4 ×). The com-
bined organic phases were dried (MgSO4), filtered, and concentrat-
ed. The crude oil was purified by flash column chromatography
(silica gel, hexane–EtOAc, 15:1) to give a white solid; yield: 52.5
mg (93.1 mmol, >99%).
1H NMR (400 MHz, 300 K, CDCl3): d = 8.11 (d, J = 8.0 Hz, 2 H,
SO2CCH), 7.39–7.23 (m, 7 H, Harom), 5.79 [dd, J = 5.7, 2.4 Hz, 1 H,
CMe(OH)CHCH], 5.46 [d, J = 5.7 Hz, 1 H, CMe(OH)CHCH], 4.35
(d, J = 14.9 Hz, 1 H, PhCHHN), 4.27 (d, J = 14.9 Hz, 1 H, Ph-
CHHN), 3.53 (d, J = 2.4 Hz, 1 H, bridgehead), 2.43 (s, 3 H, ArCH3),
1.72–1.60 (m, 1 H), 1.58 [s, 9 H, OC(CH3)3], 1.56–1.50 (m, 2 H),
1.26 [s, 3 H, C(CH3)OH], 1.15–0.70 (m, 7 H), 0.61–0.51 (m, 1 H).
1H NMR (400 MHz, 300 K, CDCl3): d = 8.02 (d, J = 8.9 Hz, 1 H,
Harom), 7.95 (d, J = 8.4 Hz, 1 H, Harom), 7.89 (d, J = 8.7 Hz, 1 H,
Harom), 7.81 (d, J = 8.1 Hz, 1 H, Harom), 7.62–7.54 (m, 3 H, Harom),
7.50–7.16 (m, 7 H, Harom), 7.05–6.98 (m, 1 H, Harom), 6.96–6.89 (m,
4 H, Harom), 6.84 (d, J = 7.4 Hz, 2 H, Harom), 4.95–4.86 [m, 1 H,
CHOP(OR)2], 4.29 (d, J = 15.8 Hz, 1 H, PhCHHN), 4.21 (d, J = 15.8
Hz, 1 H, PhCHHN), 2.93 (d, J = 6.3 Hz, 1 H, bridgehead), 2.19 (s,
3 H, ArCH3), 2.11–1.99 [m, 2 H, Hallyl + CHOP(OR)2CHH], 1.98–
1.85 [m, 1 H, CHOP(OR)2CHH], 1.70–1.46 (m, 6 H), 1.42 [s, 9 H,
OC(CH3)3], 1.35–0.72 (m, 6 H).
31P NMR (162 MHz, 300 K, CDCl3): d = 155.2.
tert-Butyl (1R,2S,5S)-7-(N-Benzyl-4-methylphenylsulfonami-
do)-6-cyclohexyl-2-[(dibenzo[d,f][1,3,2]dioxaphosphepin-6-
yl)oxy]bicyclo[3.2.0]hept-6-ene-1-carboxylate (8c)
Et3N (92 mL, 680 mmol, 7.5 equiv) and 6-chlorodiben-
zo[d,f][1,3,2]dioxaphosphepine36 (102.2 mg, 408 mmol, 4.5 equiv)
were added to a stirred soln of 6a (50.0 mg, 91 mmol, 1 equiv) in
CH2Cl2 (2.4 mL). The solvent was evaporated after 2 h and the
crude product was purified by flash column chromatography (silica
gel, hexane–EtOAc–Et3N, 18:1:1) to give a white solid; yield: 63.8
mg (83.3 mmol, 92%).
1H NMR (400 MHz, 300 K, CDCl3): d = 7.75, (d, J = 8.0 Hz, 2 H,
SO2CCH), 7.59–7.44 (m, 2 H, Harom), 7.41–7.34 (m, 2 H, Harom),
7.32–7.20 (m, 4 H, Harom), 7.16–7.07 (m, 7 H, Harom), 4.94–4.85 [m,
1 H, CHOP(OR)2], 4.41 (d, J = 16.2 Hz, 1 H, PhCHHN), 4.37 (d,
J = 16.2 Hz, 1 H, PhCHHN), 2.89 (d, J = 6.2 Hz, 1 H, bridgehead),
2.33 (s, 3 H, ArCH3), 2.18–2.04 (m, 1 H, Hallyl), 1.94–1.85 (m, 1 H),
1.84–1.72 (m, 1 H), 1.70–1.63 (m, 1 H), 1.62–1.43 (m, 4 H), 1.41
[s, 9 H, OC(CH3)3], 1.35–0.75 (m, 7 H).
tert-Butyl 2-[(tert-Butyldimethylsilyl)oxy]-7-(phenylthio)bi-
cyclo[3.2.0]hepta-2,6-diene-1-carboxylate (7d)
A 1.6 M BuLi in hexane soln (168 mL, 269 mmol, 1.7 equiv) was
added to a stirred soln of HMDS (63 mL, 300 mmol, 1.9 equiv) in
THF (3 mL) at 0 °C. After 30 min, the soln was cooled to –78 °C
and 5o (50.0 mg, 158.0 mmol, 1 equiv) was added. After 45 min,
TBDMSCl (35.7 mg, 237 mmol, 1.5 equiv) was added. After 45
min, the cooling bath was removed and the soln was stirred for 1.5
h at r.t. The reaction was quenched by the addition of Et2O and sat.
NH4Cl. The soln was extracted with Et2O (3 ×). The combined or-
ganic phases were dried (MgSO4), filtered, and concentrated. The
crude oil was purified by flash column chromatography (silica gel,
hexane–EtOAc, 15:1); yield: 28.2 mg (65.5 mmol, 41%).
1H NMR (400 MHz, 300 K, CDCl3): d = 7.54 (d, J = 7.5 Hz, 2 H,
SCCHarom), 7.40–7.23 (m, 3 H, Harom), 5.71 (s, 1 H, Holef), 4.58 (s, 1
H, Holef), 3.31 (d, J = 9.2 Hz, 1 H, bridgehead), 2.52 (dd, J = 15.9,
9.2 Hz, 1 H, Hallyl), 2.07 (d, J = 15.9 Hz, 1 H, Hallyl), 1.50 [s, 9 H,
OC(CH3)3], 0.96 [s, 9 H, SiC(CH3)3], 0.25 (s, 3 H, SiCH3), 0.22 (s,
3 H, SiCH3).
13C NMR (101 MHz, 300 K, CDCl3): d = 171.4 (CO2t-Bu), 154.0
(NC=C), 149.7 (CO, arom), 149.6 (CO, arom), 142.9 (NC=C),
138.0–122.2 (22 C, arom), 81.6 [OC(CH3)3], 74.5 (d, J = 20 Hz,
CHOH),
64.6
(CCO2t-Bu),
51.6
(PhCH2N),
45.1
{CH[OP(OR)2]CH2}, 37.9, 30.3, 30.2, 28.1 [OC(CH3)3], 26.1, 26.0,
22.3, 21.6.
31P NMR (162 MHz, 300 K, CDCl3): d = 153.4.
Monophosphite Ligands
tert-Butyl (1R,2S,5S)-7-(N-Benzyl-4-methylphenylsulfon-
amido)-6-cyclohexyl-2-[(1,3,2-dioxaphospholan-2-yl)oxy]bi-
cyclo[3.2.0]hept-6-ene-1-carboxylate (8a)
Et3N (23 mL, 163 mmol, 3 equiv) and 79.1 mM 2-chloro-1,3,2-dioxa-
phospholane in CH2Cl2 (1.0 mL, 82 mmol, 1.5 equiv) were added to
a stirred soln of 6a (30.0 mg, 54.4 mmol, 1 equiv) in CH2Cl2 (0.8
mL). The solvent was evaporated after 2.5 h and the solid residue
was washed with Et2O (4 × 3 mL). The combined organic phases
were dried in vacuo yielding a white, air-sensitive solid. The purity
was determined by NMR to be about 85%. It was not possible to fur-
ther purify the product by recrystallization or flash column chroma-
tography; yield: 20.5 mg (ca. 27 mmol, ca. 50%).
tert-Butyl (1R,2S,5S)-6-Cyclohexyl-2-[(dibenzo[d,f][1,3,2]di-
oxaphosphepin-6-yl)oxy]-7-(N-methylmethylsulfonamido)bi-
cyclo[3.2.0]hept-6-ene-1-carboxylate (8d)
Compound 5p (210.0 mg, 528 mmol, 1 equiv) in CH2Cl2 (1.5 mL)
was added to a stirred soln of NaBH4 (28.0 mg, 740 mmol, 1.4 equiv)
in MeOH (4 mL) at 0 °C. After 1 h, the reaction was quenched by
addition of H2O, brine, and CH2Cl2. The soln was extracted with
CH2Cl2 (3 ×). The combined organic phases were dried (MgSO4),
filtered, and concentrated. The crude oil was purified by flash col-
umn chromatography (silica gel, hexane–EtOAc, 4:1) to give a clear
oil; yield: 211.0 mg (528 mmol, >99%).
1H NMR (400 MHz, 300 K, CDCl3): d = 4.40–4.32 (m, 1 H,
CHOH), 3.45 (s, 1 H, OH), 3.13 (s, 3 H, SO2CH3), 3.08 [m, 1 H,
CH(OH)CHH], 3.02 (s, 3 H, NCH3), 2.82 (d, J = 6.8 Hz, 1 H,
bridgehead), 2.49–2.38 (m, 1 H, Hallyl), 2.09–1.53 (m, 7 H), 1.46 [s,
9 H, OC(CH3)3], 1.44–1.11 (m, 6 H).
1H NMR (250 MHz, 300 K, CDCl3): d = 7.70 (d, J = 8.3 Hz, 2 H,
SO2CCH), 7.32–7.13 (m, 7 H, Harom), 4.68–4.52 [m, 2 H,
CHOP(OR)2 + PhCHHN], 4.43 (d, J = 16.3 Hz, 1 H, PhCHHN),
4.26–4.13 [m,
2 H, P(OCH2CH2O)], 4.07–3.85 [m, 2 H,
P(OCH2CH2O)], 2.77 (d, J = 6.1 Hz, 1 H, bridgehead), 2.37 (s, 3 H,
ArCH3), 2.17–2.01 (m, 1 H, Hallyl), 1.67–1.40 (m, 4 H), 1.29 [s, 9 H,
OC(CH3)3], 1.24–0.70 (m, 10 H).
31P NMR (162 MHz, 300 K, CDCl3): d = 136.9.
© Thieme Stuttgart · New York
Synthesis 2012, 44, 513–526